Список проголосовавших за комментарий " On The Wires<ul><li>RedHill Biopharma Ltd. (<strong>RDHL</strong>) announced enrollment of the last patient in the Phase III study with BEKINDA 24 mg for the treatment of acute gastroenteritis and gastritis (the GUARD study).</li><li>Theravance Biopharma (<strong>TBPH</strong>) announced that it will highlight clinical data on TD-1473, a novel, potent, and orally administered pan-Janus kinase («JAK») inhibitor designed to be intestinally restricted, in a poster presentation at the upcoming 12th Congress of the European Crohn's and Colitis Organization («CCO»). Researchers will present further data from the Company's completed Phase 1 study of single-ascending and multiple-ascending doses of TD-1473, results of which were first announced in June 2016. Theravance Biopharma is developing TD-1473 as an investigational compound with the potential to treat a range of inflammatory intestinal diseases and is currently conducting a Phase 1b study of the compound in patients with moderate to severe ulcerative colitis. The 12th Congress of ECCO is being held in Barcelona, Spain, February 15-18, 2017.</li><li>One Horizon Group (<strong>OHGI</strong>) announced the launch of its optimized VoIP technology in Ghana, West Africa through a commercial software agreement with the licensed carrier AccessPLUS Communications.</li><li>Brookfield Infrastructure (<strong>BIP</strong>) comments on Petrobras (<strong>PBR</strong>) news relating to the issuance of an injunction suspending the sale by Petrobras of a 90% stake at Nova Transportadora do Sudeste S.A. to a co-led consortium. Brookfield Infrastructure intends to take all necessary measures to protect its interests and enable the NTS transaction to proceed. Brookfield Infrastructure expects that appeals against the injunction will be heard in the first half of March 2017, if not earlier.</li><li>Sevcon (<strong>SEV</strong>) announced the results of voting at its 2017 Annual Meeting of Stockholders, held on February 7, 2017. The proposal to amend our certificate of incorporation to immediately declassify the Board of Directors received 2,394,494 votes in favor, falling short of the majority of outstanding shares, 2,670,997, required to pass.</li></ul>"